Canaccord Genuity Maintains Buy Rating for Exact Sciences: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Canaccord Genuity has maintained its Buy rating for Exact Sciences (NASDAQ:EXAS) and raised its price target from $92.00 to $115.00. Exact Sciences provides cancer screening and diagnostic test products, including Cologuard and Oncotype DX.
June 23, 2023 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity maintains Buy rating for Exact Sciences and raises price target from $92.00 to $115.00, a potential 23.13% increase.
The maintained Buy rating and increased price target by Canaccord Genuity indicate a positive outlook for Exact Sciences. The new price target of $115.00 represents a potential 23.13% increase from the current share price, which could attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100